Clay B Siegall insider trades
Open-market stock purchases and sales by Clay B Siegall, President and CEO at Immunome Inc, from SEC Form 4 filings since Mar 17, 2011.
Track record: 100% of 10 scored buys are up 5% or more since purchase, averaging +85%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jul 23, 2026 | IMNM Immunome Inc | Bought (not open market) | — |
| Jul 23, 2026 | IMNM Immunome Inc | Bought (not open market) | — |
| Jun 9, 2026 | STTK Shattuck Labs, Inc | Bought | $250K |
| May 29, 2026 | STTK Shattuck Labs, Inc | Bought (not open market) | — |
| May 22, 2026 | STTK Shattuck Labs, Inc | Bought (not open market) | $139K |
| May 22, 2026 | STTK Shattuck Labs, Inc | Bought (not open market) | $139K |
| Mar 27, 2026 | IMNM Immunome Inc | Bought | $501K |
| Dec 30, 2025 | IMNM Immunome Inc | Bought | $100K |
| Dec 19, 2025 | IMNM Immunome Inc | Bought | $149K |
| Dec 19, 2025 | IMNM Immunome Inc | Sold (not open market) | — |
| Dec 18, 2025 | IMNM Immunome Inc | Bought | $1M |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc | Sold (not open market) | $371K |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc | Sold (not open market) | $209K |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc | Sold (not open market) | $315K |
Companies traded
- IMNM Immunome Inc: 11 buys, last Jul 23, 2026
- STTK Shattuck Labs, Inc: 1 buy, last Jun 9, 2026
- TRML Tourmaline Bio, Inc: other filings, last Oct 28, 2025
- SGEN Seagen Inc: 356 sales, last May 12, 2022
- NRIX Nurix Therapeutics, Inc: other filings, last May 5, 2022
- RARE Ultragenyx Pharmaceutical Inc: 3 sales, last Aug 10, 2020
- ALDR Alder Biopharmaceuticals Inc: 2 sales, last Oct 22, 2019
- MIRN Mirna Therapeutics, Inc: other filings, last Jun 29, 2016